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Abstract
Background: Hepatitis delta virus (HDV) is a defected RNA virus and requires its encoded large
antigen (LDAg) to interact with helper viral proteins (HBsAgs) during assembly. Recently, a study
demonstrated a direct binding of the LDAg C-terminus from genotype I HDV to the clathrin heavy
chain (CHC), which suggests that this interaction might facilitate HDV assembly. If LDAg binding
to clathrin is essential to HDV life cycle, a clathrin box sequence at the C-terminus of LDAg should
be conserved across all HDV. However, the C-terminal sequence of LDAg is variable among 43
HDV isolates.
Results: Based on the presence and location of clathrin box at the C-terminus of LDAg from 43
isolates of HDV, we classified them into three groups. Group 1 (13 isolates) and 2 (26 isolates)
contain a clathrin box located at amino acids 199–203 and 206–210, respectively, as found in
genotype I and genotype II. Group 3 (4 isolates) contains no clathrin box as found in genotype III.
CHC binding by three different LDAg (genotype I to III) was then tested by in vivo and in vitro
experiments. Transfection of plasmids which encode fusion proteins of EGFP and full-length of
LDAg from three genotypes into HuH-7 cells, a human heptoma cell line, was performed. GFP-pull
down assays showed that a full-length of CHC was co-precipitated by EGFP-LDI, -LDII and -LDIII
but not by EGFP. Further in vitro studies showed a full-length or fragment (amino acids 1 to 107) of
CHC can be pull-down by 13-amino-acid peptides of LDAg from three genotypes of HDV.
Conclusion: Both in vivo and in vitro studies showed that CHC can bind to various sequences of
LDAg from the three major genotypes of HDV. We therefore suggest that the clathrin-LDAg
interaction is essential to the HDV life-cycle and that sequences binding to clathrin are
evolutionarily selected, but nonetheless show the diversity across different HDV genotypes.
Background
Hepatitis delta virus (HDV) is a small defective RNA virus
with a negative-stranded genome. It requires for a helper
virus, hepatitis B virus (HBV), to supply envelope proteins
(HBsAgs) to complete virion assembly and secretion [1-
3]. The HDV genome is about 1,700 nucleotides long and
is circular in form; it appears to form an unbranched rod-
like structure due to a high degree of intra-molecular com-
plementary base-pairing [4,5]. The genome sequence of
HDV is divided into a viroid-like sequence and a protein-
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coding sequence [1,6]. It has been hypothesized that HDV
resulted from RNA recombination between a viroid
sequence and a cellular mRNA coding a DIPA (delta inter-
acting protein) protein [6,7]. Analysis of HDV sequences
from across world has revealed that those from Africa have
the highest diversity, which suggests that the first HDV
might have arisen in Africa [8,9]. After the additional iso-
lation of new HDV sequences from Africa, the classifica-
tion of HDV has been changed from one including
genotypes I to III into one involving clades 1 to 8 [8].
In the past three decades, intensive molecular biology
studies have largely revealed the functions and roles of
HDV encoded proteins in replication. During HDV repli-
cation, the coding sequence is translated into two delta
antigens (HDAgs), a small and a large form (SDAg and
LDAg), from the same reading frame; these are 195 and
214 amino acids in length, respectively [10,11]. Produc-
tion of LDAg is through a process known as RNA editing,
which is performed by cellular ADAR [12,13]; this con-
verts the amber stop codon (UAG) of SDAg into a tryp-
tophan codon (UGG), resulting in an extra 19 or 20
amino acids at the C-terminus of LDAg [14]. SDAg is
essential for HDV replication while LDAg antagonizes the
function of SDAg and is required to interact with HBsAg
during virion assembly and maturation [15,16]. There is a
CaaX-box (211CRPQ214,  211CTPQ214, and 211CTQQ214 in
various HDV genotypes, see Fig. 1A) at the C-terminus of
LDAg, which acts as a signal of isoprenylation. Mutation
of the isoprenylation signal of LDAg leads to a failure of
virion assembly and secretion [17-19].
In addition to the isoprenylation signal sequence, a
nuclear exporting signal (NES) has also been identified at
the C-terminus of LDAg [20]. Within the common 195-
amino-acid sequence of SDAg and LDAg, two putative
leucine-zipper motifs, an RNA binding motif, and two
nuclear localization signals have been identified [21-24].
Both SDAg and LDAg are phosphoprotiens with a differ-
ent degree of modification [25]. After they have been
either phosphorylated by PKC [26], CKII [18,26], PKR
[27] or ERK1/2 [28], they affect HDV replication or are tar-
geted to SC-35 speckles [18,26-28]. Both acetylation of
HDAg at lysine-72 and methylation of SDAg at arginine-
13 have also been demonstrated to influence HDV repli-
cation [29-31]. Conservation of these post-translational
sites of HDAg among all known HDV genotypes suggests
that the cellular enzymes responsible for the post-transla-
tional modifications of HDAg are at least partial if not all
involved in HDV replication.
Co-infection and super-infection of HDV with HBV usu-
ally cause more severe liver disease than an HBV single
infection [32]. The various HDV genotypes show different
geographical distributions and are associated with differ-
ent disease patterns [7,33]. HDV genotype I is distributed
world-wide and has been linked to a wide spectrum of dis-
eases, ranging from fulminant hepatitis to asymptomatic
chronic liver disease. Genotype II is found mainly in Asia,
including Japan, Taiwan and Siberia, and seems to give
rise to a less severe disease than genotype I. Genotype III
is mainly found in the north part of South America and
produces a severe form of fulminant hepatitis [33]. The
mechanism of HDV pathogenesis would seem to result
from complicated interactions between HDV, HBV, and/
or host factors and is not completely understood.
Two recent studies have indicated that LDAg rather than
SDAg might play a significant role in HDV pathogenesis
[34,35]. One study demonstrated a direct binding of
LDAg to Smad-3, which modulates TGF-β signaling to
activate plasminogen activator inhibitor-1 expression and
c-Jun-induced signal cascades; this would seem to lead to
liver cirrhosis [35]. The other study demonstrated that the
cytoplasmic form of LDAg binds to the clathrin heavy
chain (CHC) and further suggested that this LDAg-CHC
interaction is required for HDV assembly. Furthermore,
the LDAg-CHC interaction would seem to interfere with
the clathrin-mediated endocytosis and exocytosis, which
might finally lead to the hepatocytes damage [34]. How-
ever, the clathrin-box (199LFPAD203) identified in the
LDAg of genotype I is not conserved in the same position
in genotype II and III (Fig. 1A). This study was carried out
with the aim of verifying whether the clathrin-binding
activity is conserved across the three major genotypes of
LDAgs.
Results
The alignment of LDAg amino acid sequences from the
three HDV genotypes indicates two features: 1) the com-
mon 195-amino-acid sequence shared by HDAg is con-
served because it contains many functional motifs and
post-translational modification sites, which are important
for viral replication and maturation, and 2) the unique C-
terminal sequence of LDAg is highly variable and differs
in numbers of amino acids, in which genotype I and II
have 19 residues while genotype III has 20 residues (Fig.
1A). Additionally, the presence of consensus sequence of
the clathrin box (LϕxϕD/E) [36,37] and its location are
also different at the C-terminus of LDAg (Fig. 1A). There
is a clathrin box located at amino acids 199–203 in geno-
type I and a clathrin box at amino acids 206–210 in gen-
otype II while no clathrin box in genotype III. Further
alignment of all known HDV sequences by the C-terminal
end of LDAg shows that when 43 isolates across clades 1
to 8 were compared, they could be divided into three dif-
ferent groups. Group 1 contains a clathrin box
[LFP(A,S,V)D] located at amino acids 199–203 as found
in genotype I. Group 2 contains a clathrin box (LPLLE)
located at amino acids 206–210 as found in genotype II.Virology Journal 2009, 6:31 http://www.virologyj.com/content/6/1/31
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The features of LDAg amino acid sequences of HDV and the synthetic oligonucleotides encoding the 13-amino-acid peptide of  LDAg Figure 1
The features of LDAg amino acid sequences of HDV and the synthetic oligonucleotides encoding the 13-
amino-acid peptide of LDAg. (A) The amino acid (in one-letter symbols) alignment of full-length of LDAg from the three 
genotypes. Genotype I is from American strain (accession number M28267), genotype II from Taiwan-3 strain (accession 
number U19598), and genotype III from Peru strain (accession number L22063). The putative clathrin binding domains are 
shown by rectangle boxes and the last 19 or 20 amino acids of LDAg are highlighted by bold face letters. The consensus amino 
acids for post-translational modification are indicated as follows: Ac (acetylation) at amino acid 72, Pi (phosphorylation) at posi-
tions of 2, 123, and 177 and Py (isoprenylation) at the position 211. The amino acid positions are indicated by numbers. (B) 
Two complementary oligonucleotides were designed for expression of the corresponding short amino acid sequences (as indi-
cated in one-letter symbols above the oligonucletides) of LDAg. The 5'- and 3'-end of the oligonucleotides were designed to 
include the restriction sites EcoRI and SalI, respectively. The restriction site immediately next to SalI is EcoRV, which was 
designed specifically to allow quick clone selection.
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Finally, group 3 contains no clathrin box as found in gen-
otype III (Table 1). Among 43 HDV isolates, 13 sequences
belong to group 1, 26 belong to group 2 and 4 are group 3.
If clathrin-binding by LDAg is important to the HDV life-
cycle, this property should be conserved across all geno-
types of HDV. To answer this question, we designed in vivo
CHC binding experiments to test whether exogenously
expressed EGFP-LD can bind to endogenous CHC or not.
HuH-7 cells, a human hepatoma cell line, were first trans-
fected with the pEGFP-LD series of plasmids and treated
with TNF-α at 24 h post-transfection for 2 h so that the
EGFP-LD would behave like authentic LDAg [38] and be
translocated from the nucleus to cytoplasm after the TNF-
α treatment [39]. The transfected cells were immunopre-
cipitated by anti-GFP. This was followed by Western blot
analysis, which showed that CHC was co-precipitated by
all three fusion proteins, EGFP-LDI, EGFP-LDII, and
EGFP-LDIII (Fig. 2, lanes 7–9), but not by EGFP (Fig. 2,
lane 6). The amount of CHC co-precipitated with EGFP-
LDI, -LDII, and LD-III was quantified after normalization
and found to have a ratio of 1: 2.6: 2.2, respectively, aver-
aged across three independent experiments. This indicates
that LDAg binding to CHC is conserved and that the bind-
ing capacity varies across the three genotypes of HDV.
To verify the CHC binding by LDAg of genotype II and III
is indeed through the C-terminus of LDAg as demon-
strated by genotype I [34], we expressed the 13-amino-
acid peptide (amino acid positions 198 to 210) of LDAg
which is fused to GST, in E. coli (Fig. 3A). Purified GST-
LDC(198–210)  proteins bound to glutathione-Sepharose
beads were then incubated with HuH-7 cell lysate for 16
h. The cell lysate and GST fusion protein mixtures were
then spun down and analyzed by Western blotting. The
results showed that the full-length CHC from HuH-7 cells
was able to bind to the GST fusion proteins containing the
peptide from the three LDAg (Fig. 3B, lanes 7–9) but not
to GST only (Fig. 3B, lane 6). The normalized amount of
CHC binding to the LDAg terminus of genotype I, II and
III was in a ratio of 1: 1.6: 1.3, respectively, averaged across
three independent experiments. Thus, the binding capac-
ity of genotype II and III was lower than that found by the
in vivo experiments as shown in Fig. 2. Nevertheless, this
result indicates that the 13-amino-acid peptide of the
GST-LDIIIC(198–210)protein, which is without an identifia-
ble clathrin-box, was still able to bind to full-length CHC
and that this binding to CHC was stronger than the GST-
LDIC(198–210) protein that does contain a clathrin box.
Since no consensus sequence of a clathrin box is present
in the C-terminus of genotype III LDAg, we further veri-
fied whether the CHC fragment (amino acid 1 to 107) is
the specific binding site for the peptide
(198FTPPPPGYYWVPG210) of genotype III LDAg. A frag-
ment of CHC fused with hexahistidine was expressed in E.
coli (Fig. 4A) and then purified by nickel beads. The glu-
tathione-Sepharose beads bound with GST fusion pro-
teins containing the 13-amino-acid peptide of LDAg from
the various genotypes was then individually incubated
with 6XHis-CHC(1–107) for 16 h. The spun down mixtures
were separated by SDS-PADE and stained by silver. The
results showed that the fragment of CHC(1–107) was pulled
down by beads containing GST fusion protein (Fig. 4B,
lanes 3–5) but not by those containing GST only (Fig. 4B,
lane 2). The amount of CHC fragment pulled down by
GST-LDIC(198–210), GST-LDIIC(198–210), and GST-LDI-
IIC(198–210) was averaged from three independent experi-
ments and showed the ratio 1: 1.4: 0.7. Taken all these
results together, it would seem that the LDAg of genotype
II, either as a full-length protein or a 13-amino-acid pep-
tide, had the highest binding capacity to the full-length or
107-amino-acid peptide of CHC as comparing three gen-
otypes. The LDAg of genotype III had the second highest
binding capacity to the full-length of CHC (Fig. 2A and
Fig. 3B), however, had the lowest binding capacity to the
fragment of CHC.
Discussion
In this study, we have demonstrated that binding to CHC
by the C-terminus of LDAg is conserved across all three
major genotypes of HDV, although their amino acid
sequences (198LLFPADPPFSPQS210  in genotype I,
198GPSPPQQRLPLLE210  in genotype II, and
198FTPPPPGYYWVPG210 in genotype III) are highly varia-
ble in this region (Fig. 1A). Based on the variable
sequences, the 43 HDV isolates analyzed can be classified
into three groups (Table 1) and the three genotypes (I to
III), described earlier in this study, each are represented by
one of these groups.
It is reasonable to speculate that the CHC binding by the
13-amino-acid peptide of genotype II LDAg is through a
putative clathrin box (LPLLE) that is located between
amino acids 206 to 210. It has the highest binding capa-
bility to CHC among the three genotypes and this might
be a result of a clathrin box at the most proximal end to
the C-terminus. Whether such strong binding to CHC
reduces genotype II LDAg's interaction with HBsAg and
results in poorer packaging by HBsAg as found by Hsu et
al. [40] is not determinable from these results. How the
peptide of genotype III LDAg, lacking of a clathrin box,
binds to CHC is also unclear. There are two possibilities.
Firstly, the proline-rich stretch present in genotype III
LDAg, which is similar to that of synaptojanin, might
serve as a clathrin binding sequence [41]. Alternatively,
cellular factors, such as AP-2, might form a complex with
genotype III LDAg, through the 205YYWV208 or 206YWVP209
motif [41], and CHC. The results show a weaker binding
affinity to the CHC(1–107) fragment produced from E. coliVirology Journal 2009, 6:31 http://www.virologyj.com/content/6/1/31
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Table 1: Three groups of the C-terminus of LDAg from 43 HDV isolates based on the presence and location of clathrin box
Clades Isolate Extra a.a. residues Clathrin Box
HDV-1 Ethiopia WDILFPSDPPFSPQS-CRPQ LFP(A,S,V)D
group 1
US-1 WDILFPADPPSSPQS-CRPQ
US-2 WDILFPADPPFSPQS-CRPQ
Nagasaki-2 WDILFPVDPPFSPQS-CRPQ
Taiwan WDLLFPADPPFSPQS-CRPQ
TW2667 WDILFPADPPFSPQS-CRPQ
China WDILFPADPPFSPQS-CRPQ
Italy WDILFPADPPFSPQS-CRPQ
Nauru WDILFPSDPPFSPQS-CRPQ
Cagliari WDLLFPADPPFSPQS-CRPQ
HDV-Iran WDILFPSDPPFSPQS-CRPQ
Lebanon WDILFPSDPPFSPQS-CRPQ
Somalia WDILFPSDPPFSPQS-CRPQ
HDV-2 Japan WVSPSPPQQRLPLLE-CTPQ LPLLE
group 2
Taiwan-3 WVHPSPPQQRLPLLE-CTPQ
Miyako-37 WVRPSPPQQRLPLLE-CTPQ
TW2476 WVRPSPPQQRLPLLE-CTPQ
Yakut-26 WVNPVPPGQRLPLLE-CTPQ
Yakut-62 WVNPAPPGQRLPLLE-CTPQ
HDV-3 Peru-1 WYGFTPPPPGYYWVPGCTQQ None
group 3
VnzD8624 WYGFTPPPPGYYWVPGCTQQ
VnzD8375 WYGFTPPPPGYYWVPGCTQQ
VnzD8349 WYGFTPPPPGYYWVPGCTQQ
HDV-4 Miyako WVDPGRPSPRLPLLE-CTPQ LPLLE
group 2
L215 WVGPGSPSPRFPLLE-CTPQ
Miyako-36 WVNPQPPPPRLPLLE-CTPQ
Taiwan-Tw-2b WVSPQPPPPRLPLLE-CTPQ
AF209859 WVSPQPPPPRLPLLE-CTPQ
Tokyo WVNPQPPPPRLPLLE-CTPQ
HDV-5 dFr2600 WVNPGPXPPRLPLLE-CTPQ LPLLE
group 2
dFr2005 WVSPGSPSPRLPLLE-CTPQ
dFr47 WVNPGPRPPRLPLLE-CTPQ
dFr910 WVDPGPRPPRLPLLE-CTPQ
dFr73 WVSPGAPSPRLPLLE-CTPQ
dFr2703 WVSPXPXPPRLPLLE-CTPQ
HDV-6 dFr48 WGNTPPRPPRLPLLE-CTPQ LPLLE
group 2
dFr2139 WGNGPPRSPRLPLLE-CTPQ
dFr2627 WGNTPPRPPRLPLLE-CTPQ
HDV-7 dFr45 WGNTPPRPPRLPLLE-CTPQ LPLLE
group 2
dFr2158 WGPSPTPPPRLPLLE-CTPQ
HDV-8 dFr2072 WGQSPPPPPRLPLLE-CTPQ LPLLE
group 2
dFr644 WGQRPPPPPRLPLLE-CTPQ
dFr2736 WGQQPPPPPRLPLLE-CTPQVirology Journal 2009, 6:31 http://www.virologyj.com/content/6/1/31
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than to the full-length of CHC from the HuH-7 cell lysate
by the peptide of genotype III LDAg (Fig. 4B vs. Fig. 3B).
This suggests that firstly, cell factors are possibly involved
in the genotype III LDAg binding to CHC and/or sec-
ondly, the fragment of CHC might have a different confor-
mation from the full-length CHC. This change
conformation might be less favorable to genotype III
LDAg peptide binding. Based on the above results, we
believe a further investigation to elucidate the hypotheses
is warranted.
It has been demonstrated that the LDAg is required for
interacting with HBsAgs to form mature virions or empty
particles containing LDAg [16,42]. Questions on where
and how HDV virions and empty particles are produced
and mature remain unanswered. It is possible that the
interaction between clathrin and the C-terminus of LDAg
may assist HDV budding into the lumen of various intra-
cellular membranes, such as ER or Golgi apparatus. Thus
the LDAg may act as a late (L) domain similar to the situ-
ation during budding of many retroviruses [36,37]. There
are three known classes of L domains for retroviruses,
namely, PTAP, PPXY, and YXXL. The 202PPGY205 sequence
is present in genotype III LDAg, but is not present in gen-
otype I and II, and this fits well into the second class of L
domain. Whether this sequence functions as an L domain
for genotype III HDV budding remains to be tested.
The fact that clathrin binding by LDAg is conserved across
all genotypes must reflect its biological importance to the
HDV life-cycle. We therefore postulate that any sequence
at the C-terminus of LDAg that is able to bind to clathrin
will be selected during evolution and this explains the
great diversity across the various genotypes. Whether
LDAg binding to clathrin, which may impair the normal
functioning of clathrin, is one of causes of HDV pathogen-
esis as suggested by Huang et al. [34] remains to be eluci-
dated, although many clathrin-associated diseases have
been reported [43,44].
Methods
Plasmids used in this study
The cDNAs coding LDAg from different HDV genotypes,
American strain of genotype I (accession number
An in vivo binding assay of EGFP-LDs to clathrin Figure 2
An in vivo binding assay of EGFP-LDs to clathrin. HuH-7 cells were transfected by various plasmids, as indicated above 
the blot, to allow expression of the EGFP-LDs. The total cell lysate and anti-GFP precipitated proteins were analyzed for CHC 
(2A), GFP (2B), and actin (2C) by Western blotting. NC (lane 1) represents non-transfection HuH-7 cells as a control. Lanes 2 
to 5 are total cell lysates and lanes 6 to 9 are the anti-GFP immunoprecipitated proteins.
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An in vitro binding assay of LDAg peptides to HuH-7 cellular clathrin Figure 3
An in vitro binding assay of LDAg peptides to HuH-7 cellular clathrin. (A) Expression and purification of GST and the 
GST fusion proteins with the 13-amino-acid peptides of LDAg in E. coli. Total E. coli protein profiles are in even number lanes 
and purified proteins are in odd number lanes. The top gel was stained with Coomassie blue and the bottom gel was analyzed 
for GST. GST fusion proteins from different LDAg genotypes are indicated above the gel. Protein makers are shown to the left 
of the gel. (B) Western blot analysis for E. coli expressed LDAg peptide binding to CHC from a HuH-7 cell lysate. The top gel 
was detected for CHC, middle gel for actin, and bottom gel for GST. The GST and GST fusion proteins used for the binding 
assay are indicated above the gel. Lanes 1 to 5 are total cell lysate and lanes 6–9 are the GST-pull downs.
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An in vitro binding assay of LDAg peptides to CHC(1–107) fragment produced from E. coli Figure 4
An in vitro binding assay of LDAg peptides to CHC(1–107) fragment produced from E. coli. (A) Expression profile 
and purification of the fragment of CHC in E. coli. The top gel was stained with Coomassie blue and the bottom gel was 
detected by anti-His antibody. The protein makers are indicated to the left of the gel. (B) E. coli expressed GST and GST fusion 
proteins as shown in Fig. 3 were incubated with purified CHC as shown in (A). The GST pull-down products were analyzed by 
SDS-PAGE and silver stained. The proteins used for the pull-down are indicated above the gel and their migration positions are 
indicated by a black arrowhead (GST-LD), a gray arrowhead (GST) and a white arrowhead (CHC). Open circle (lane 1) indi-
cates an unknown protein co-purified with CHC from E. coli.
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M28267), Taiwan-3 strain of genotype II (accession
number U19598), and Peru-1 strain of genotype III
(accession number L22063), were used in this study and
have been described previously [33,45,46]. In this study,
plasmids were divided into two groups: one for transfec-
tion into human hepatoma cells, HuH-7 [47], and the
other for transformation into E. coli for protein expres-
sion. For transfection studies, the three genotypes of the
LDAg coding sequence were constructed into pEGFP-C3
using BglII and EcoRI cloning sites as described previously
[38]. The plasmids for protein expression were con-
structed by the insertion of synthetic oligonucleotides
(Fig. 1B) downstream of GST in pGEX-4T1 using EcoRI
and  SalI sites; this gave pGST-LDIC(198–210), pGST-
LDIIC(198–210), and pGST-LDIIIC(198–210), respectively.
These clones were first selected checking for the presence
of the EcoRV site and then verified by nucleotide sequenc-
ing. The cDNA fragment of human clathrin heavy chain
containing amino acid 1 to 107 was amplified by RT-PCR
and then inserted downstream of hexahistidine-tag
sequence of pET-15b to give p6XHis-CHC(1–107); which
was used to express 6XHis-CHC(1–107) protein in E. coli.
The plasmid was verified by nucleotide sequencing.
Antibodies and affinity beads
The antibodies used in this study were purchased from
different commercial companies. Anti-GFP was obtained
from Clontech (California, USA) and Chemicon (Califor-
nia, USA). Anti-GST and anti-6XHis were bought from
LTK BioLaboratories (Taoyuan, Taiwan). Anti-clathrin
heavy chain was purchased from BD (California, USA).
Anti-actin was obtained from Novus Biologicals (Colo-
rado, USA). The secondary antibody conjugated with
horseradish peroxidase was bought from Chemicon. Glu-
tathione beads and nickel beads were purchased from GE
(New Jersey, USA) and Qiagen (California, USA), respec-
tively.
Cell culture and plasmid transfection
HuH-7 is a fully-differentiated human hepatoma cell line
[47] and was cultured at 37°C under 5% CO2 using Dul-
becco's modified Eagle's medium supplement with 10%
fetal bovine serum, penicillin (100 U/ml), streptomycin
(100 μg/ml), and 1% non-essential amino acid. Cells at
60% confluence in a 10 cm Petri dish were transfected
with 10 μg of plasmid by the calcium phosphate/DNA
precipitation method or by adding lipofectamin 2000
(Invitrogen; California, USA). The transfection rate of
each experiment was determined by the GFP expression
under a fluorescence microscope.
Protein expression in E. coli and purification
E. coli strain BL21 (DE3) was used to express GST and GST
fusion proteins as well as 6XHis-CHC(1–107). Bacteria were
grown in LB medium supplement with 100 μg/ml ampi-
cillin while vigorously shaken at 37°C until an O.D. 600
nm of 0.6 was reached. Production of protein was induced
by the addition of 1 mM IPTG to the medium for 1 to 3 h.
The resulting fusion proteins were further purified by one
step binding to either glutathione affinity beads or nickel
beads as appropriate and then analyzed by SDS-PAGE and
Western blotting.
Immunoprecipitation, GST-protein pull down and 
Westernblotting
At 24 h post-transfection with pEGFP-C3, pEGFP-LDI,
pEGFP-LDII or pEGFP-LDIII into HuH-7 cells, the cells
were treated with TNF-α (30 ng/ml) for 2 h [39]. Cells
were lysed and immunoprecipitatd by anti-GFP. The pre-
cipitated proteins were fractionated by SDS-PAGE and
electrotransferred onto PVDF membranes. The membrane
was then incubated with anti-clathrin, anti-GFP, and anti-
actin antibodies individually. After incubation with the
secondary antibody conjugated with horseradish peroxi-
dase, the blots were developed by enhanced chemilumi-
nescence using a commercial kit (Pierce; Illinois, USA).
The intensity of the protein bands was quantified by the
program Image J software (NIH, Maryland, USA). In order
to compare the pull-down efficiency of the different gen-
otype LDAgs, the amount of CHC was normalization
against actin and the amount pulled down by genotype I
EGFP-LD was designated as 1. Three independent results
were averaged and compared. Glutathione Sepharose 4B
beads containing various GST fusion proteins were incu-
bated with HuH-7 cell lysates or E. coli produced 6XHis-
CHC(1–107) for 16 h at 4°C. After three washes with 0.05%
Tween-20 in PBS (phosphate buffered saline), the pro-
teins bound to the beads were analyzed and quantified by
Western blot and Image J software as described above.
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